Both companies are in the same sector (Health Care) — compared here on their latest annual financials and current price.
Valuation favors JOHNSON & JOHNSON, Profitability favors JOHNSON & JOHNSON, Safety favors JOHNSON & JOHNSON, Growth favors ELI LILLY & Co. (A relative comparison within the same universe/sector — not a buy/sell recommendation.)
| Dimension | ELI LILLY & Co | JOHNSON & JOHNSON |
|---|---|---|
| Valuation | ★☆☆☆☆ | ★★☆☆☆ |
| Profitability | ★★★★☆ | ★★★★★ |
| Safety | ★☆☆☆☆ | ★★☆☆☆ |
| Growth | ★★★★☆ | ★★★☆☆ |
| Metric | ELI LILLY & Co | JOHNSON & JOHNSON |
|---|---|---|
| P/E | 254.8x | 18.7x |
| P/B | 93.54x | 8.56x |
| ROE% | 36.7% | 45.8% |
| Op. Margin% | – | – |
| Debt Ratio% | 452% | 141% |
| Div. Yield% | 0.33% | 1.72% |
| Market Cap | $1,335.0B | $657.7B |
| Health Score | 36.7 | 56.4 |
Bold, accent-colored figures mark the better value for that metric. Data: latest SEC filings and current price. Health Score percentiles are computed across the full universe. Not investment advice. ← Back to the screener